Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2008

01.06.2008

Second cancers in patients with male breast cancer: a literature review

verfasst von: Tal Grenader, Anthony Goldberg, Linda Shavit

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The risk of second malignancies among female breast cancer patients has been studied for decades. In contrast, very little is known about second primary tumors in men. Risk factors for breast cancer in men, including genetic, hormonal and environmental factors, provide parallels to the etiology of breast cancer in women. This review considers the literature related to the risk of developing a second cancer in patients with male breast cancer.

Materials and methods

A systematic review of the literature between 1966 and 2007 was conducted and acceptable articles used for analysis. All retrieved articles were screened to identify any papers that had been missed. Studies were included if they discussed the risk of subsequent malignancy in patients with male breast cancer.

Results

Patients with history of male breast cancer have an increased risk of a second ipsilateral, or contralateral breast cancer (standardized incidence ratio 30–110). The risk of subsequent contralateral breast cancer was highest in men under 50 years of age at the time of the diagnosis of the initial cancer. The data on non-breast second primary cancers is diverse. One study has suggested an increased incidence of cancers of the small intestine, prostate, rectum and pancreas, and of non-melanoma skin cancer and myeloid leukaemia. Other investigators did not find an increase in the overall risk of subsequent cancer development in men diagnosed initially with primary breast cancer. Although sarcoma, lung and esophageal cancers are well recognized complications of radiation therapy for female breast cancer, there is no evidence for the association of these cancers following radiation therapy in male breast cancer.

Conclusions

Although the incidence of second primary cancer in patients with primary male breast cancer requires further study, male breast cancer survivors should probably undergo periodic screening for the early detection of second breast cancers and other adverse health effects.
Literatur
1.
2.
Zurück zum Zitat Sasco AJ, Lowenfels AB, Pasker-de Jong J. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538–49.PubMedCrossRef Sasco AJ, Lowenfels AB, Pasker-de Jong J. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538–49.PubMedCrossRef
3.
Zurück zum Zitat Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004;101(1):51–7.PubMedCrossRef Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004;101(1):51–7.PubMedCrossRef
4.
Zurück zum Zitat Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83(1):77–86.PubMedCrossRef Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83(1):77–86.PubMedCrossRef
5.
Zurück zum Zitat Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22(4):735–42.PubMedCrossRef Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22(4):735–42.PubMedCrossRef
6.
Zurück zum Zitat Struewing JP, Coriaty ZM, Ron E, et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999;65:1800–2.PubMedCrossRef Struewing JP, Coriaty ZM, Ron E, et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999;65:1800–2.PubMedCrossRef
7.
Zurück zum Zitat Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997;60:1079–84.PubMed Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997;60:1079–84.PubMed
8.
Zurück zum Zitat Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998;58:1367–71.PubMed Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998;58:1367–71.PubMed
9.
Zurück zum Zitat Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59:995–8.PubMed Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59:995–8.PubMed
10.
Zurück zum Zitat Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410–9.PubMedCrossRef Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410–9.PubMedCrossRef
11.
Zurück zum Zitat The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310–6.CrossRef The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310–6.CrossRef
12.
Zurück zum Zitat Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259–72.PubMedCrossRef Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259–72.PubMedCrossRef
13.
Zurück zum Zitat Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14(1):20–6.PubMedCrossRef Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14(1):20–6.PubMedCrossRef
14.
Zurück zum Zitat D’Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer 1995;71:1359–62.PubMed D’Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer 1995;71:1359–62.PubMed
16.
Zurück zum Zitat Volm MD, Talamonti MS, Thangavelu M, Grtadishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 1997;64:74–8.PubMedCrossRef Volm MD, Talamonti MS, Thangavelu M, Grtadishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 1997;64:74–8.PubMedCrossRef
17.
Zurück zum Zitat Forloni F, Giovilli M, Pecis C, et al. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year old male. J Endocrinol Investig 2001;24:454. Forloni F, Giovilli M, Pecis C, et al. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year old male. J Endocrinol Investig 2001;24:454.
18.
Zurück zum Zitat Schell SR, Montague ED, Spanos WJ Jr, et al. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982;50(6):1191–4.PubMedCrossRef Schell SR, Montague ED, Spanos WJ Jr, et al. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982;50(6):1191–4.PubMedCrossRef
19.
Zurück zum Zitat Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984;71(9):711–4.PubMedCrossRef Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984;71(9):711–4.PubMedCrossRef
20.
Zurück zum Zitat Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347(8):567–75.PubMedCrossRef Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347(8):567–75.PubMedCrossRef
21.
Zurück zum Zitat Hemminki K, Scelo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005;92(7):1288–92.PubMedCrossRef Hemminki K, Scelo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005;92(7):1288–92.PubMedCrossRef
22.
Zurück zum Zitat Hemminki K, Granstrom C. Re: risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94(24):1892.PubMed Hemminki K, Granstrom C. Re: risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94(24):1892.PubMed
23.
Zurück zum Zitat Cutuli BF, Lacroze M, Dilhuydy JM, et al. Breast cancer in men: incidence and types of associated previous synchronous and metachronous cancers. Bull Cancer 1992;79(7):689–96.PubMed Cutuli BF, Lacroze M, Dilhuydy JM, et al. Breast cancer in men: incidence and types of associated previous synchronous and metachronous cancers. Bull Cancer 1992;79(7):689–96.PubMed
24.
Zurück zum Zitat Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94(17):1330–2.PubMed Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94(17):1330–2.PubMed
25.
Zurück zum Zitat Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578–83.PubMed Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578–83.PubMed
26.
Zurück zum Zitat Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat 2001;66:171–2.PubMedCrossRef Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat 2001;66:171–2.PubMedCrossRef
27.
Zurück zum Zitat Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758–61.PubMedCrossRef Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758–61.PubMedCrossRef
28.
Zurück zum Zitat Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992;84:1114–7.PubMedCrossRef Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992;84:1114–7.PubMedCrossRef
29.
Zurück zum Zitat Karlsson CT, Malmer B, Wiklund F, Gronberg H. Breast cancer as a second primary in patients with prostate cancer-estrogen treatment or association with family history of cancer? J Urol 2006;176(2):538–43.PubMedCrossRef Karlsson CT, Malmer B, Wiklund F, Gronberg H. Breast cancer as a second primary in patients with prostate cancer-estrogen treatment or association with family history of cancer? J Urol 2006;176(2):538–43.PubMedCrossRef
30.
Zurück zum Zitat Leibowitz SB, Garber JE, Fox EA, et al. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J 2003;9(3):208–12.PubMedCrossRef Leibowitz SB, Garber JE, Fox EA, et al. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J 2003;9(3):208–12.PubMedCrossRef
31.
Zurück zum Zitat Thellenberg C, Malmer B, Tavelin B, Gronberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003;169(4):1345–8.PubMedCrossRef Thellenberg C, Malmer B, Tavelin B, Gronberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003;169(4):1345–8.PubMedCrossRef
32.
Zurück zum Zitat Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75–9.PubMedCrossRef Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75–9.PubMedCrossRef
33.
Zurück zum Zitat Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86(13):983–8.PubMedCrossRef Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994;86(13):983–8.PubMedCrossRef
34.
Zurück zum Zitat Wang LE, Bondy ML, de Andrade M, et al. Gender difference in smoking effect on chromosome sensitivity to gamma radiation in a healthy population. Radiat Res 2000;154(1):20–7.PubMedCrossRef Wang LE, Bondy ML, de Andrade M, et al. Gender difference in smoking effect on chromosome sensitivity to gamma radiation in a healthy population. Radiat Res 2000;154(1):20–7.PubMedCrossRef
35.
Zurück zum Zitat Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combinationof national statistics with two case–control studies. BMJ 2000;321(7257):323–9.PubMedCrossRef Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combinationof national statistics with two case–control studies. BMJ 2000;321(7257):323–9.PubMedCrossRef
36.
Zurück zum Zitat Neugut AI, Meadows AT, Robinson E. Introduction. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia, PA: Lippincott Williams & Wilkins; 1999, p. 1–12. Neugut AI, Meadows AT, Robinson E. Introduction. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia, PA: Lippincott Williams & Wilkins; 1999, p. 1–12.
37.
Zurück zum Zitat Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30(6):740–8.PubMedCrossRef Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30(6):740–8.PubMedCrossRef
38.
Zurück zum Zitat Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002;52(2):406–14.PubMed Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002;52(2):406–14.PubMed
Metadaten
Titel
Second cancers in patients with male breast cancer: a literature review
verfasst von
Tal Grenader
Anthony Goldberg
Linda Shavit
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2008
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-008-0042-5

Weitere Artikel der Ausgabe 2/2008

Journal of Cancer Survivorship 2/2008 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.